A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis.
Binet Jl,A. Auquier,Dighiero G,Claude Chastang,H. Piguet,J. Goasguen,G. Vaugier,G. Potron,P. Colona,F. Oberling,Mark J. Thomas,G. Tchernia,Cl. Jacquillat,P. Boivin,C. Lesty,M. T. Duault,M. Monconduit,S. Belabbes,F. Gremy +18 more
TLDR
A new three‐stage classification in three prognostic groups only requires clinical examination and routine hemogram, has a good prognostic value which was confirmed on the series of Montserrat and Rozman (146 patients), and should therefore be helpful in planning new clinical trials.Abstract:
Survivals of two series of CLL patients (99 from a retrospective series and 196 from a prospective series) were studied separately The three main staging systems (Rai, Binet, Rundles) agreed well, but as far as survival is concerned, too many stages are defined The authors performed a Cox multivariate analysis of survival in order to isolate important prognostic factors at diagnosis and to use them to build a simple three-stage classification Thrombopenia and anemia appeared as the most important risk factors Among the nonanemic and nonthrombopenic patients, the number of involved areas was clearly related to prognosis in the authors' two series This study allowed the authors to propose a new classification in three prognostic groups Group C: anemia (Hb less than 10 g) and/or thrombopenia (platelets less than 100,000/mm3); about 15% of the patients; median of 2 years Group B: no anemia, no thrombopenia, three or more involved areas (counting as one each of the following: axillary, cervical, inguinal, lymph nodes, whether unilateral or bilateral, spleen and liver); about 30% of patients; median of 7 years Group A: no anemia, no thrombopenia, less than three involved areas; about 55% of patients; the survival of this group does not seem different from that of the French population of the same age and sex distribution This three-stage classification only requires clinical examination and routine hemogram, has a good prognostic value which was confirmed on the series of Montserrat and Rozman (146 patients), and should therefore be helpful in planning new clinical trialsread more
Citations
More filters
Book
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
TL;DR: Thank you very much for reading who classification of tumours of haematopoietic and lymphoid tissues, and maybe you have knowledge that, people have look hundreds of times for their chosen readings like this, but end up in malicious downloads.
Journal ArticleDOI
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
Hartmut Döhner,Stephan Stilgenbauer,Axel Benner,Elke Leupolt,Alexander Kröber,Lars Bullinger,Konstanze Döhner,Martin Bentz,Peter Lichter +8 more
TL;DR: Genomic aberrations in chronic lymphocytic leukemia are important independent predictors of disease progression and survival and have implications for the design of risk-adapted treatment strategies.
Journal ArticleDOI
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
Michael Hallek,Bruce D. Cheson,Daniel Catovsky,Federico Caligaris-Cappio,Guillaume Dighiero,Hartmut Döhner,Peter Hillmen,Michael J. Keating,Emili Montserrat,Kanti R. Rai,Thomas J. Kipps +10 more
TL;DR: The International Workshop on Chronic Lymphocytic Leukemia (IWCLL) to provide updated recommendations for the management of CLL in clinical trials and general practice is provided.
Journal ArticleDOI
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.
Rajendra N. Damle,Tarun Wasil,Tarun Wasil,Tarun Wasil,Franco Fais,Franco Fais,Franco Fais,Fabio Ghiotto,Fabio Ghiotto,Fabio Ghiotto,Angelo Valetto,Angelo Valetto,Angelo Valetto,Steven L. Allen,Steven L. Allen,Steven L. Allen,Aby Buchbinder,Aby Buchbinder,Aby Buchbinder,Daniel R. Budman,Daniel R. Budman,Daniel R. Budman,Klaus Dittmar,Klaus Dittmar,Klaus Dittmar,Jonathan E. Kolitz,Jonathan E. Kolitz,Jonathan E. Kolitz,Stuart M. Lichtman,Stuart M. Lichtman,Stuart M. Lichtman,Philip Schulman,Philip Schulman,Philip Schulman,Vincent Vinciguerra,Vincent Vinciguerra,Vincent Vinciguerra,Kanti R. Rai,Kanti R. Rai,Kanti R. Rai,Manlio Ferrarini,Manlio Ferrarini,Manlio Ferrarini,Nicholas Chiorazzi,Nicholas Chiorazzi,Nicholas Chiorazzi +45 more
TL;DR: In this paper, cellular immunophenotypic studies were performed on a cohort of randomly selected IgM(+) B-chronic lymphocytic leukemia (B-CLL) cases for which Ig V(H) and V(L) gene sequences were available.
Journal ArticleDOI
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
Michael Hallek,Kirsten Fischer,Günter Fingerle-Rowson,Anna-Maria Fink,Raymonde Busch,Jiří Mayer,Manfred Hensel,Georg Hopfinger,G D Hess,U. Von Grünhagen,Matthias Bergmann,John Catalano,Pier Luigi Zinzani,Federico Caligaris-Cappio,John F. Seymour,Alain Berrebi,Ulrich Jäger,Bruno Cazin,Marek Trneny,Anne Westermann,Clemens M. Wendtner,Barbara Eichhorst,Peter Staib,Andreas Bühler,Dirk Winkler,Thorsten Zenz,S Böttcher,Matthias Ritgen,Myriam Mendila,Michael Kneba,Hartmut Döhner,Stephan Stilgenbauer +31 more
TL;DR: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab improves progression-free survival and overall survival in patients with chronic lymphocytic leukaemia, and the results suggest that the choice of a specific first-line treatment changes the natural course of chronic lymphocytes.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Book ChapterDOI
Regression Models and Life-Tables
TL;DR: The analysis of censored failure times is considered in this paper, where the hazard function is taken to be a function of the explanatory variables and unknown regression coefficients multiplied by an arbitrary and unknown function of time.
Journal ArticleDOI
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.
Richard Peto,M.C. Pike,P. Armitage,N. E. Breslow,David Cox,S V Howard,N Mantel,Klim McPherson,Julian Peto,Pete Smith +9 more
TL;DR: Efficient methods of analysis of randomized clinical trials in which the authors wish to compare the duration of survival among different groups of patients are described.
Journal ArticleDOI
Clinical staging of chronic lymphocytic leukemia.
Kanti R. Rai,Arthur Sawitsky,Eugene P. Cronkite,Arjun D. Chanana,Robert N. Levy,Bernard S. Pasternack +5 more
TL;DR: The proposed staging system was an equally accurate indicator for survival when applied to two other previously published studies of large series of patients and sex and age were shown to be poor predictors of survival after adjustment for stage.
Journal ArticleDOI
A clinical staging system for chronic lymphocytic leukemia. Prognostic significance
Binet Jl,Michel Leporrier,Dighiero G,Charron D,G. Vaugier,H. Merle Beral,J. C. Natali,Martine Raphael,B. Nizet,J. Y. Follezou +9 more
TL;DR: The five‐stage anatomico‐clinical classification system suggested appears to be the dominant prognostic factor and may thus serve as a guideline for therapeutic strategy.
Related Papers (5)
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.
Rajendra N. Damle,Tarun Wasil,Tarun Wasil,Tarun Wasil,Franco Fais,Franco Fais,Franco Fais,Fabio Ghiotto,Fabio Ghiotto,Fabio Ghiotto,Angelo Valetto,Angelo Valetto,Angelo Valetto,Steven L. Allen,Steven L. Allen,Steven L. Allen,Aby Buchbinder,Aby Buchbinder,Aby Buchbinder,Daniel R. Budman,Daniel R. Budman,Daniel R. Budman,Klaus Dittmar,Klaus Dittmar,Klaus Dittmar,Jonathan E. Kolitz,Jonathan E. Kolitz,Jonathan E. Kolitz,Stuart M. Lichtman,Stuart M. Lichtman,Stuart M. Lichtman,Philip Schulman,Philip Schulman,Philip Schulman,Vincent Vinciguerra,Vincent Vinciguerra,Vincent Vinciguerra,Kanti R. Rai,Kanti R. Rai,Kanti R. Rai,Manlio Ferrarini,Manlio Ferrarini,Manlio Ferrarini,Nicholas Chiorazzi,Nicholas Chiorazzi,Nicholas Chiorazzi +45 more